According to data that experts hailed as a potential breakthrough in how the virus is controlled, an experimental antiviral tablet produced by Merck & Co (MRK.N) might half the risks of dying or being hospitalized for individuals most at risk for getting severe COVID-19.
If approved by the US, molnupiravir, which is meant to induce mistakes into the virus’s genetic coding, would be the first oral antiviral treatment for COVID-19.
